Bezuclastinib

From Wikipedia, the free encyclopedia

Other namesCGT-9486, PLX-9486
Legal status
  • Investigational
CAS Number
PubChem CID
Bezuclastinib
Clinical data
Other namesCGT-9486, PLX-9486
Legal status
Legal status
  • Investigational
Identifiers
  • 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC19H17N5O
Molar mass331.379 g·mol−1
3D model (JSmol)
  • CC1=C(NN=C1C(=O)NC2=CN=C3C(=C2)C=C(N3)C4=CC=CC=C4)C
  • InChI=1S/C19H17N5O/c1-11-12(2)23-24-17(11)19(25)21-15-8-14-9-16(22-18(14)20-10-15)13-6-4-3-5-7-13/h3-10H,1-2H3,(H,20,22)(H,21,25)(H,23,24)
  • Key:NVSHVYGIYPBTEZ-UHFFFAOYSA-N

Bezuclastinib is an investigational new drug that is being evaluated for the treatment of gastrointestinal stromal tumors and systemic mastocytosis. It acts as an inhibitor of tyrosine-protein kinase KIT.[1][2] [3][4]


Related Articles

Wikiwand AI